Immunocore Holdings Plc ADR (IMCR)

Apr 2, 2025, 8:00 AM EDT - 25 days ago

Immunocore to present at upcoming investor conferences

Mar 10, 2025, 3:00 PM EDT - 6 weeks ago

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

Feb 27, 2025, 8:11 AM EST - 2 months ago

Immunocore: A Commercial Biotech Nearing Its Pivotal Break-Even Point

Feb 26, 2025, 1:24 PM EST - 2 months ago

Immunocore Holdings plc (IMCR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:00 AM EST - 2 months ago

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Feb 19, 2025, 7:00 AM EST - 2 months ago

Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

Jan 10, 2025, 7:00 AM EST - 3 months ago

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 3 months ago

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 7:00 AM EST - 4 months ago

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Dec 23, 2024, 7:00 AM EST - 4 months ago

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Dec 3, 2024, 1:00 AM EST - 5 months ago

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Nov 6, 2024, 7:00 AM EST - 6 months ago

Immunocore reports third quarter financial results and provides a business update

Sep 14, 2024, 3:00 AM EDT - 8 months ago

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Sep 12, 2024, 4:05 PM EDT - 8 months ago

Immunocore to present at the 2024 Cantor Global Healthcare Conference

Aug 30, 2024, 11:40 AM EDT - 8 months ago

Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak

Aug 12, 2024, 4:12 AM EDT - 9 months ago

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Aug 11, 2024, 6:53 AM EDT - 9 months ago

Immunocore Holdings plc (IMCR) Q2 2024 Earnings Call Transcript

Jun 1, 2024, 8:00 AM EDT - 11 months ago

Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response

May 31, 2024, 4:05 PM EDT - 11 months ago

Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024

May 30, 2024, 4:00 PM EDT - 11 months ago

Immunocore to present at the Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 11 months ago

Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma

May 24, 2024, 12:00 PM EDT - 1 year ago

Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.

GILD MRNA

May 8, 2024, 7:00 AM EDT - 1 year ago

Immunocore reports first quarter financial results and provides a business update

Apr 24, 2024, 10:00 AM EDT - 1 year ago

Immunocore announces upcoming presentation and posters at ASCO 2024

Mar 5, 2024, 4:30 PM EST - 1 year ago

Immunocore presented two posters at CROI 2024

Feb 28, 2024, 10:57 AM EST - 1 year ago

Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 7:34 AM EST - 1 year ago

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Feb 22, 2024, 7:00 AM EST - 1 year ago

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

Feb 21, 2024, 7:00 AM EST - 1 year ago

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Jan 30, 2024, 11:30 PM EST - 1 year ago

Immunocore Prices Upsized Convertible Senior Notes Offering

Jan 29, 2024, 4:05 PM EST - 1 year ago

Immunocore Announces Proposed Convertible Senior Notes Offering

Jan 5, 2024, 7:00 AM EST - 1 year ago

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation

Jan 3, 2024, 7:00 AM EST - 1 year ago

Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 1 year ago

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 1, 2023, 5:42 PM EDT - 1 year ago

Immunocore: First Half Of 2024 IMC-F106C Data Expected

Nov 1, 2023, 4:01 PM EDT - 1 year ago

Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023

Oct 21, 2023, 8:45 AM EDT - 1 year ago

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

Oct 6, 2023, 7:01 AM EDT - 1 year ago

Immunocore announces upcoming presentation and posters at ESMO 2023

Aug 27, 2023, 12:28 PM EDT - 1 year ago

Immunocore: KIMMTRAK Adoption Continues At Rapid Pace, Expanding To New Markets, Reiterate Buy

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 3, 2023, 8:00 AM EDT - 1 year ago

Immunocore to report second quarter 2023 financial results and host call on August 10, 2023

Jul 31, 2023, 2:43 PM EDT - 1 year ago

August MDA Breakout Stocks Week 31 - 2023: High-Frequency Gainers To Give You An Edge

AAPL AMGN ARDX CELH COIN CSCO CVX

Jun 11, 2023, 3:49 AM EDT - 2 years ago

Immunocore Holdings: Unlocking The Immune System's Hidden Potential

Jun 3, 2023, 7:00 AM EDT - 2 years ago

Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO

May 10, 2023, 7:00 AM EDT - 2 years ago

Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update

May 3, 2023, 4:30 PM EDT - 2 years ago

Immunocore to present at the Bank of America Securities 2023 Health Care Conference

Apr 18, 2023, 7:00 AM EDT - 2 years ago

Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival

Apr 11, 2023, 7:00 AM EDT - 2 years ago

Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Immunocore to present four posters at AACR Annual Meeting 2023

Mar 1, 2023, 1:33 PM EST - 2 years ago

Immunocore Holdings plc (IMCR) Q4 2022 Earnings Call Transcript